STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	(a): 28 dni, EMA Naslov ne vsebuje, da gre za opazovalno študijo. (b): Povzetek vsebuje cilj, načrt raziskave, metode, rezultate in zaključke. *Str. 1*
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Obširena predstavitev ozadja. *Str. 2 – 3, poglavje 2*
Objectives	3	State specific objectives, including any prespecified hypotheses	Str. 3, 2. poglavje, zadnji stavek
Methods			
Study design	4	Present key elements of study design early in the paper	Primeren opis. *Str. 3, poglavje 3.2*
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Opisana časovna raporeditev študije (v katerem tednu je posameznik izvajal določene naloge). Potek raziskave je povzet samo meseci in leti (brez točnih datumov). Opredeljena lokacija. Opis zbiranja podatkov. *Str. 3-4, poglavja 4.1, 4.2, 4.3, 4.4*
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (*b*) For matched studies, give matching criteria and number of exposed and unexposed	(a): Kriteriji za preiskovance so našteti v protokolu študije. To je zapisano v članku. *Str. 3, poglavje 4.1* (b) Ne omenjajo enakih raziskav.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Definiran je izid študije, spremenljivke so podrobno definirane v protokolu študije (je napisano v članku), zunanji dejavniki v študiji niso bili privzeti (omenjeno v omejitvah študije), definirano visoko in nizko tveganje (effect modifiers), diagnostična merila so podorbno opisana v protokolu študije, navedena pa v študiji. *Str. 3-4, poglavje 4.3, 4.4, 4.5* *Str. 9, zadnji odstavek*
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Navedeni viri podatkov za spremenljivke (npr, samomorilno razmišljanje – EMA, spanje in aktivnost – nosljiva naprava, …). Navedeno, da je zbiranje opisano v protokolu študije. Opisana delitev v dve skupini (nizko in visoko rizična skupina). *Str. 3-4, poglavje 4.2, 4.3, slika* *Str. 1, povzetek*

Bias	9	Describe any efforts to address potential sources of bias	Določene pristranskosti so omenjene, določene delno – nekatere so omenjene v protokolu, nekatere v omejitvah študije. Omenjena je pristranskost convenience sampling, uporabljena metoda EMA, izpad udeležencev iz študije, težavo samoporočanja, nezajemanje nekaterih zunanjih spremenljivk, … *Str. 3, poglavje 4.1, 4.3* *Str. 9*
Study size	10	Explain how the study size was arrived at	Opisano v protokolu študije.
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Opisn namen in način delitve v dve skupini. *Str. 1, povzetek,* *Str. 3, poglavje 4.1*
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding (*b*) Describe any methods used to examine subgroups and interactions (*c*) Explain how missing data were addressed (*d*) If applicable, explain how loss to follow-up was addressed (*e*) Describe any sensitivity analyses	(a): Navedeno, da so metode opisane v protokolu študije. *Str. 4, poglavje 4.5* (b): Opisane metode za primerjavo razlik med skupinama v protokolu študije. (c): Niso imeli mankajočih podatkov, napisan izpad sodelujočih iz študije. *Str. 3, poglavje 4.1* (e): Omenjno, kako se težko posplošuje rezultate. *Str. 9*
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	(a): Opredeljeno skupno število sodelujočih, izpad sodelujočih, ni opredeljeno kdaj so izstopili iz študije, je opredeljeno zakaj so izstopili. Vsi sodelujejo v vseh fazah raziskave. *Str. 3, poglavje 4.1* (b) Ni potrebno. (c) Ne vsebuje.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	(a): Predstavljeno v tabeli. *Str. 6-7, tabela 1* (b): Ni mankajočih podatkov. (c): 28 dni, v povprečju 25.1 dni. *Str. 3, 4.3, odstavek 2*
Outcome data	15*	Report numbers of outcome events or summary measures over time	Opredeljeno končno število opazovanih posameznikov, ni vmesnih rezultatov. Podani končni rezultati statistične analize.

			Str. 8, tabela 2, *Str. 4, poglavje 5*
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (*b*) Report category boundaries when continuous variables were categorized (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	(a): Podani končni rezultati stat. analize s pripadajočimi SD in p-vrednostmi. *Str. 8, tabela 2* *Str. 4, poglavje 5*
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Tabela 1-skupno in po obeh skupinah Str. 7
Discussion			
Key results	18	Summarise key results with reference to study objectives	Poglobljen opis rezultatov, dodani rezultati, p-vrednosti v oklepajih. Interpretacija rezultatov. *Str. 4-8, poglavje 5*
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Opisane v diskusiji in že pred tem omenjene v protokolu študije. *Str. 9*
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Podana interpretacija rezultatov, opis drugih študij in izpostavljeno kaj je drugače. Ni podanih številskih rezultatov drugih študij, samo povzetki. *Str. 7-10, poglavja 6, 6.1* *Str. 2-3, poglavje 2*
Generalisability	21	Discuss the generalisability (external validity) of the study results	*Str. 9*
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Zapisano na začetku med naslovom in povzetkom. *Str. 1*

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.